Stock PHAS.Q PHASEBIO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials PhaseBio Pharmaceuticals, Inc.

Equities

PHAS.Q

US7172241090

Biotechnology & Medical Research

End-of-day quote OTC Markets
Other stock markets
 06:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
0.000001 USD 0.00% Intraday chart for PhaseBio Pharmaceuticals, Inc. 0.00% 0.00%
Apr. 19 First Amended Combined Liquidation Plan and Disclousre Statement Filed by PhaseBio Pharmaceuticals, Inc. CI
Feb. 07 Fifth Motion for Exclusivity Period Extension Approved For PhaseBio Pharmaceuticals, Inc. CI

Valuation

Fiscal Period: December 2018 2019 2020 2021
Capitalization 1 75.7 175.8 98.67 125.5
Enterprise Value (EV) 1 22.17 118.2 85.24 92.83
P/E ratio -0.69 x -4.28 x -0.99 x -0.87 x
Yield - - - -
Capitalization / Revenue 113,322,858 x 74,444,002 x 308,330,650 x 11,588,483 x
EV / Revenue 33,186,630 x 50,069,584 x 266,368,150 x 8,570,663 x
EV / EBITDA -1.13 x -2.99 x -1.01 x -0.88 x
EV / FCF -1,402,104 x -4,408,596 x -1,507,990 x -1,914,466 x
FCF Yield -0% -0% -0% -0%
Price to Book 1.49 x 2.93 x -3.93 x -1.35 x
Nbr of stocks (in thousands) 24,498 28,766 29,365 48,090
Reference price 2 3.090 6.110 3.360 2.610
Announcement Date 3/26/19 3/30/20 3/15/21 3/24/22
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net sales - - 0.668 2.361 0.32 10.83
EBITDA 1 -9.409 -8.442 -19.54 -39.56 -84.35 -105.6
EBIT 1 -9.501 -8.538 -19.64 -39.74 -84.86 -107.4
Operating Margin - - -2,940.72% -1,683.02% -26,517.5% -991.25%
Earnings before Tax (EBT) 1 -9.22 -10.25 -23.85 -39.25 -98.56 -129.5
Net income 1 -9.22 -10.25 -23.85 -39.25 -98.56 -131.1
Net margin - - -3,569.76% -1,662.3% -30,801.56% -1,210.15%
EPS 2 -12.41 -13.78 -4.495 -1.427 -3.392 -2.984
Free Cash Flow - -3.357 -15.81 -26.81 -56.52 -48.49
FCF margin - - -2,366.92% -1,135.73% -17,663.79% -447.68%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/21/18 9/21/18 3/26/19 3/30/20 3/15/21 3/24/22
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 Q1 2020 Q2 2020 Q3 2020 Q4 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales 1 0.32 - - - - 10.34 0.335 0.158 0.117 0.208
EBITDA 1 - - - - - - - - -18.23 -25.31
EBIT 1 -14.29 -24.1 -20.49 -25.98 -25.65 -21.05 -28.58 -32.09 -18.23 -25.31
Operating Margin -4,465% - - - - -203.65% -8,530.15% -20,307.59% -15,579.49% -12,169.23%
Earnings before Tax (EBT) 1 -14.9 -28.14 -25.14 -30.38 -27.36 -27.08 -31.92 -43.11 -11.14 -16.66
Net income 1 -14.9 -28.14 -25.14 -30.38 -27.36 -28.68 -31.92 -43.11 -11.14 -16.66
Net margin -4,657.81% - - - - -277.41% -9,529.55% -27,284.81% -9,522.22% -8,012.02%
EPS 2 -0.5200 -0.9800 -0.8600 -1.030 -0.8700 -0.6000 -0.6600 -0.8500 -0.2300 -0.3400
Dividend per Share - - - - - - - - - -
Announcement Date 5/12/20 8/11/20 11/12/20 3/15/21 5/13/21 8/12/21 11/10/21 3/24/22 5/16/22 8/12/22
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2016 2017 2018 2019 2020 2021
Net Debt 1 - 2.08 - - - -
Net Cash position 1 3.72 - 53.5 57.5 13.4 32.7
Leverage (Debt/EBITDA) - -0.2458 x - - - -
Free Cash Flow - -3.36 -15.8 -26.8 -56.5 -48.5
ROE (net income / shareholders' equity) - 716% -106% -70.8% -567% 222%
ROA (Net income/ Total Assets) - -58.6% -31.8% -34.1% -79.8% -121%
Assets 1 - 17.49 74.9 115 123.5 108.3
Book Value Per Share 2 -117.0 -131.0 2.080 2.090 -0.8600 -1.930
Cash Flow per Share 2 5.000 18.00 2.490 2.570 0.9600 0.8700
Capex 1 0.09 0.22 0.12 0.96 1.31 2.68
Capex / Sales - - 17.81% 40.66% 410% 24.73%
Announcement Date 9/21/18 9/21/18 3/26/19 3/30/20 3/15/21 3/24/22
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PHASEBIO PHARMACEUTICALS, INC. Stock PhaseBio Pharmaceuticals, Inc.
0.00% 49
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PHAS.Q Stock
  4. Financials PhaseBio Pharmaceuticals, Inc.